All In Biotech

Drug Trial Radar · NCT01474109

Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients

Prospective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Ischemic Digital Ulcers Associated With Systemic Sclerosis

Last checked: Nov 19, 2026Latest source record: Jan 6, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 289 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

289

Actual

Start

Dec 2011

Primary completion

Nov 2013

Study completion Nov 2013

Sponsor

Lead sponsor
ActelionJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Nov 18, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The DUAL-1 study is designed as a multicenter, double-blind two-period study with an initial fixed 16-week Period 1, followed by a Period 2 of variable duration. All patients completing Period 1 will continue on their original randomized treatment into Period 2, until the last randomized patient has completed Period 1. Patients will be randomized in a 1:1:1 ratio (macitentan 3mg: macitentan 10mg: placebo). The primary objective is to demonstrate the effect of macitentan on the reduction of the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcers. Other objectives include: * the evaluation of the efficacy of macitentan on hand functionality and DU burden at Week 16 in SSc patients with ongoing DU disease. * the evaluation of the safety and tolerability of macitentan in these patients. * the evaluation of the efficacy of macitentan on time to first DU complication during the entire treatment period.

Conditions

  • Systemic Sclerosis
  • Ulcers

Interventions

  • macitentan 3mgDrug

    macitentan 3mg tablet once daily

  • macitentan 10mgDrug

    macitentan 10mg tablet once daily

  • placeboDrug

    matching placebo once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence Rate of New Digital Ulcers (DUs) up to Week 16Time frame: Baseline to week 16

Locations

77 sites in 18 countries. Site status is shown where the registry gives one.

  • University of Arizona Arthritis Center

    Tucson, Arizona

  • UCLA Medical School - Rheumatology Division Rehabilitation Center

    Los Angeles, California

  • Arthritis & Rheumatic Disease Specialties

    Aventura, Florida

  • Sarasota Arthritis Research Center

    Sarasota, Florida

  • Ochsner Medical Center

    New Orleans, Louisiana

  • The Johns Hopkins University School of Medicine

    Baltimore, Maryland

  • University of Michigan - Scleroderma Program

    Ann Arbor, Michigan

  • Michigan State University

    Grand Rapids, Michigan

  • University of Medicine & Dentistry of New Jersey, UMDNJ Scleroderma Program

    New Brunswick, New Jersey

  • The Center for Rheumatology

    Albany, New York

  • Shanahan Rheumatology and Immunotherapy, PLLC

    Raleigh, North Carolina

  • The Cleveland Clinic Foundation

    Cleveland, Ohio

  • Altoona Center for Clinical Research

    Duncansville, Pennsylvania

  • University of Pittsburgh Department of Rheumatology

    Pittsburgh, Pennsylvania

  • Medical University of South Carolina

    Charleston, South Carolina

  • Royal Adelaide Hospital

    Adelaide, Australia

  • Wesley Hospital, Thoracic Department

    Auchenflower, Australia

  • Royal Prince Alfred Hospital

    Camperdown, Australia

  • St Vincent's Hospital

    Fitzroy, Australia

  • Menzies Research Institute

    Hobart, Australia

  • Gomel Regional Clinical Hospital

    Homyel, Belarus

  • Healthcare Institution "Minsk City Hospital #1"

    Minsk, Belarus

  • Healthcare Institution "Minsk Clinical Hospital #9"

    Minsk, Belarus

  • Multiprofile Hospital for Active Treatment "Sveti Pantaleymon"

    Pleven, Bulgaria

  • MHAT "Kaspela" EOOD Plovdiv - Rheumatology Ward

    Plovdiv, Bulgaria

  • MHAT "Sv. Ivan Rilski" EAD Sofia - Clinic of Rheumatology

    Sofia, Bulgaria

  • Rheumatology Research Associates

    Edmonton, Alberta, Canada

  • St. Paul's Hospital

    Vancouver, British Columbia, Canada

  • St. Joseph's Health Care

    London, Ontario, Canada

  • Mount Sinai Hospital

    Toronto, Ontario, Canada

  • CHUS Hopital Fleurimont

    Sherbrooke, Quebec, Canada

  • Prosalud

    Santiago, Chile

  • Private Office Marta Aliste

    Santiago, Chile

  • Hospital San Juan de Dios

    Santiago, Chile

  • Centro de Estudios Clinicos V

    Viña del Mar, Chile

  • Medicity S.A.S.

    Bucaramanga, Colombia

  • Servimed E.U.

    Bucaramanga, Colombia

  • Klinicki Bolnicki Centar Osijek

    Osijek, Croatia

  • University Hospital Centre Rijeka

    Rijeka, Croatia

  • Klinički bolnički centar Split

    Split, Croatia

Showing 40 of 77 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.